Biotest AG: Biotest AG: Biotest proposes capital increase from capital funds and share split to General Meeting
Biotest AG / Key word(s): Corporate Action
17.03.2015 15:45
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
/
Ad-hoc RELEASE
Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)
Biotest AG: Biotest proposes capital increase from capital funds and share
split to General Meeting
- Proposed capital increase without issuing new shares
- Proposed share split with the relation of one to three
Dreieich, 17 March 2015. Biotest AG will propose a capital increase from
capital funds and a share split with the relation of one to three by means
of a reclassification of the share capital to its Annual General Meeting on
7 May 2015. Biotest share prices have increased significantly in recent
years. The proposed share split is intended to promote the liquidity and
accessibility of the Biotest shares and to make the Biotest shares even
more attractive also for a broader group of investors.
The share capital of Biotest AG currently amounts to EUR 33,767,639.04 and
is divided into 6,595,242 ordinary shares and into 6,595,242 preference
shares without voting rights. Thus, one ordinary or preference share has a
proportional amount of the share capital of EUR 2.56. After the
implementation of the capital increase from capital funds by EUR
5,803,812.96 to EUR 39,571,452.00 without issuing new shares and the share
split, each current holder of one existing ordinary or preference share
would hold in future three ordinary or preference shares with a
proportional amount of the share capital of EUR 1.00.
The agenda of the Annual General Meeting resolved today by the Supervisory
Board and the Management Board will be published presumably on 25 March
2015. In accordance with the proposed share split, Biotest also proposed
several amendments to the articles of association, e.g. appropriation of
profit and the remuneration of the Supervisory Board.
Biotest Aktiengesellschaft
Board of Management
Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.de
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has more than 2,100
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
17.03.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
